Trial · NCT02527343
Participant flow90
How many started, completed or left each group, period by period.
1 to 20 of 90
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| RT Period: Weeks 1 to 52 | STARTED | Randomized Treatment Period: Placebo | 19 | |
| RT Period: Weeks 1 to 52 | STARTED | Randomized Treatment Period: Volanesorsen | 21 | |
| RT Period: Weeks 1 to 52 | STARTED | Randomized Post-Treatment Follow-up Period: Placebo | 0 | |
| RT Period: Weeks 1 to 52 | STARTED | Randomized Post-Treatment Follow-up Period: Volanesorsen | 0 | |
| RT Period: Weeks 1 to 52 | STARTED | Open-Label Extension Period (OLE and OLE Post-Treatment Follow-up): Placebo/Volanesorsen | 0 | |
| RT Period: Weeks 1 to 52 | STARTED | Open-Label Extension Period (OLE and OLE Post-Treatment Follow-up): Volanesorsen/Volanesorsen | 0 | |
| RT Period: Weeks 1 to 52 | COMPLETED | Randomized Treatment Period: Placebo | 13 | |
| RT Period: Weeks 1 to 52 | COMPLETED | Randomized Treatment Period: Volanesorsen | 14 | |
| RT Period: Weeks 1 to 52 | COMPLETED | Randomized Post-Treatment Follow-up Period: Placebo | 0 | |
| RT Period: Weeks 1 to 52 | COMPLETED | Randomized Post-Treatment Follow-up Period: Volanesorsen | 0 | |
| RT Period: Weeks 1 to 52 | COMPLETED | Open-Label Extension Period (OLE and OLE Post-Treatment Follow-up): Placebo/Volanesorsen | 0 | |
| RT Period: Weeks 1 to 52 | COMPLETED | Open-Label Extension Period (OLE and OLE Post-Treatment Follow-up): Volanesorsen/Volanesorsen | 0 | |
| RT Period: Weeks 1 to 52 | NOT COMPLETED | Randomized Treatment Period: Placebo | 6 | |
| RT Period: Weeks 1 to 52 | NOT COMPLETED | Randomized Treatment Period: Volanesorsen | 7 | |
| RT Period: Weeks 1 to 52 | NOT COMPLETED | Randomized Post-Treatment Follow-up Period: Placebo | 0 | |
| RT Period: Weeks 1 to 52 | NOT COMPLETED | Randomized Post-Treatment Follow-up Period: Volanesorsen | 0 | |
| RT Period: Weeks 1 to 52 | NOT COMPLETED | Open-Label Extension Period (OLE and OLE Post-Treatment Follow-up): Placebo/Volanesorsen | 0 | |
| RT Period: Weeks 1 to 52 | NOT COMPLETED | Open-Label Extension Period (OLE and OLE Post-Treatment Follow-up): Volanesorsen/Volanesorsen | 0 | |
| RT Post Treatment Follow-up: Weeks 54-65 | STARTED | Randomized Treatment Period: Placebo | 0 | |
| RT Post Treatment Follow-up: Weeks 54-65 | STARTED | Randomized Treatment Period: Volanesorsen | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02527343/flow